background
pauciti
licens
monoclon
antibodi
mab
infecti
diseas
arena
strongli
contrast
readi
avail
therapeut
use
condit
aim
narr
review
aim
assess
potenti
monoclon
antibodybas
intervent
infecti
diseas
sourc
review
literatur
via
medlin
databas
perform
complement
publish
offici
document
licens
antiinfect
mab
addit
ongo
trial
identifi
search
clinic
trial
registr
platform
clinicaltrialsgov
content
identifi
infect
mab
ad
therapeut
armamentarium
stress
potenti
repres
readili
avail
protect
tool
biothreat
newli
emerg
reemerg
infecti
agent
review
histor
context
main
featur
mab
assert
potenti
wider
applic
cite
relev
exampl
ongo
therapeut
develop
factor
hinder
success
introduct
mab
larger
scale
outlin
thought
offer
possibl
address
limit
implic
mab
may
repres
import
tool
treat
prevent
infect
occur
reason
suffici
preval
justifi
demand
exist
altern
deem
fulli
adequ
futur
initi
need
address
prohibit
cost
encount
develop
process
feasibl
largescal
administr
altern
modal
merit
explor
order
ensur
optim
prospect
regulatori
success
earli
dialogu
compet
author
encourag
e
pelfren
clin
microbiol
infect
bezlotoxumab
becam
second
monoclon
antibodi
author
use
throughout
european
econom
area
direct
infecti
agent
target
clostridium
difficil
toxin
b
aim
prevent
recurr
infect
adult
high
risk
repeat
bout
follow
much
earlier
eu
regulatori
approv
palivizumab
administ
prevent
seriou
lower
respiratori
tract
diseas
requir
hospit
caus
respiratori
syncyti
viru
rsv
children
high
risk
diseas
licens
two
monoclon
antibodi
mab
nearli
two
decad
apart
illustr
gap
date
clinic
develop
therapeut
tool
infect
consist
experi
regulatori
author
us
food
drug
administr
fda
grant
similarli
phrase
label
unit
state
product
addit
fda
recent
licens
ibalizumab
rescu
therapi
heavili
treatmentexperienc
adult
multidrugresist
infect
also
previous
approv
raxibacumab
obiltoxaximab
intend
treatment
inhal
anthrax
combin
appropri
antibacteri
medicin
prophylaxi
altern
therapi
avail
appropri
latter
two
product
assess
fda
accord
anim
rule
larg
reli
efficaci
data
gener
relev
anim
model
gener
use
mab
view
attract
biodefens
measur
counter
deliber
threat
technolog
platform
may
also
offer
rapid
protect
newli
emerg
reemerg
infecti
agent
treatment
prophylaxi
avail
wit
exampl
ongo
research
mab
treat
patient
middl
east
respiratori
syndrom
experiment
use
tobacco
plantederiv
mixtur
mab
zmapp
ebola
viru
diseas
outbreak
western
africa
provid
addit
exampl
respect
interestingli
pauciti
current
licens
mab
infecti
diseas
arena
strongli
contrast
readi
avail
therapeut
use
condit
mainli
oncolog
chronic
inflammatori
rheumat
afflict
inde
diseas
area
mab
global
gener
sizeabl
yearli
incom
narr
review
revisit
potenti
applic
mab
target
infect
outlin
prospect
success
therapeut
develop
undertook
search
medlin
complet
regard
trial
review
antibodybas
therapeut
infecti
diseas
term
use
differ
combin
follow
therapeut
antibodi
monoclon
infecti
diseas
well
pathogenspecif
term
result
limit
englishlanguag
report
survey
document
publish
januari
march
methodolog
complement
publish
offici
document
antiinfect
mab
licens
date
eu
us
regulatori
author
trial
identifi
search
clinic
trial
registr
platform
clinicaltrialsgov
histor
immun
sera
use
treat
prevent
infecti
diseas
avail
vaccin
antibiot
polyclon
sera
hyperimmun
sera
still
use
condit
rabi
diphtheria
tetanu
botul
sera
typic
administ
rapid
protect
requir
follow
known
exposur
unvaccin
individu
vaccin
nonexist
previous
acquir
immun
wane
hyperimmun
sera
mab
deploy
irrespect
preexist
immun
protect
statu
equal
may
benefit
immunocompromis
host
howev
avoid
disadvantag
attribut
sera
deriv
immunoglobulin
potenti
exceedingli
low
transmiss
infecti
hazard
batch
variabl
year
monoclon
antibodi
engin
evolv
first
licens
monoclon
antibodi
indic
prevent
acut
kidney
transplant
reject
use
murin
hybridoma
techniqu
earli
commerci
success
mab
limit
howev
avail
suitabl
myeloma
cell
line
also
occurr
advers
immun
reaction
provok
human
antimous
antibodi
respons
recogn
setback
use
techniqu
limit
unwant
effect
whilst
also
enhanc
effector
function
chimer
mouseehuman
antibodi
first
replac
murin
hybridoma
recent
human
ie
antibodi
structur
contain
less
nonhuman
sequenc
fulli
human
mab
develop
new
express
tool
becam
avail
phage
display
librari
transgen
mice
chines
hamster
ovari
cho
base
biomanufactur
highli
scalabl
plant
technolog
well
possibl
produc
mab
use
human
b
cell
isol
subject
convalesc
vaccin
thu
current
method
made
product
effici
importantli
use
human
human
mab
pose
fewer
safeti
concern
oppos
older
techniqu
serum
therapi
exquisit
specif
hallmark
mab
gener
harbour
low
potenti
offtarget
advers
reaction
although
make
vulner
escap
mutant
potenti
render
therapeut
measur
ineffect
henc
drawback
justifi
develop
mab
cocktail
antibodi
constitu
bind
differ
epitop
also
altern
antibodi
format
engin
simultan
address
differ
target
involv
pathophysiolog
process
bispecif
antibodi
aim
ensur
enhanc
potenc
breadth
protect
develop
includ
antigenbind
fab
fragment
singl
chain
variabl
fragment
scfv
pair
link
differ
way
creat
format
combin
optim
size
halflif
activ
safeti
well
novel
deliveri
system
antibodyeantimicrobi
conjug
radioimmunoconjug
effector
function
modifi
fc
domain
chang
may
enhanc
affin
fc
receptor
phagocyt
cell
nk
cell
b
cell
henc
enforc
antibodydepend
kill
whilst
mutat
lead
increas
bind
affin
neonat
fc
receptor
fcrn
contribut
extend
halflif
antibodi
principl
mab
could
target
wide
rang
biolog
agent
encompass
bacteri
viral
pathogen
fungi
associ
toxin
action
exert
either
directli
eg
prevent
cell
entri
neutral
toxin
via
indirect
mechan
eg
modul
inflammatori
respons
promot
opson
phagocytosi
date
licens
antibacteri
mab
target
exotoxin
antigeneantibodi
complex
primarili
remov
via
reticuloendotheli
system
instead
mab
may
bind
structur
cell
surfac
compon
protein
exopolysaccharid
subsequ
direct
bactericid
clearanc
immun
system
depend
cytotox
antibodi
complement
depend
regard
pharmacodynam
mode
action
vari
amongst
candid
product
current
develop
notwithstand
previou
disappoint
translat
research
activ
target
staphylococcu
aureu
pseudomona
aeruginosa
develop
far
b
et
al
safeti
toler
singl
administr
human
monoclon
antibodi
patient
sever
pneumonia
caus
staphylococcu
aureu
first
man
trial
abstract
paper
present
european
congress
clinic
microbiolog
infecti
diseas
inde
era
increas
awar
intensifi
effort
mitig
antimicrobi
resist
threat
mab
may
offer
welcom
addit
therapeut
toolkit
although
unlik
compet
directli
convent
antimicrobi
treat
seriou
bacteri
infect
mab
might
act
synergist
measur
administ
concurr
date
promis
result
effect
shown
anim
model
antibodi
administr
expect
provid
less
select
pressur
crossresist
may
preserv
gut
microflora
dan
import
consider
view
expand
knowledg
role
human
gut
microbiom
health
diseas
nevertheless
success
wide
introduct
mab
treat
establish
bacteri
infect
larg
depend
readi
specif
pathogen
identif
necessit
invest
research
valid
pointofcar
rapid
diagnost
eg
pcrbase
fluoresc
insitu
hybrid
technolog
allow
prompt
target
therapi
also
effect
singl
dose
last
one
month
use
recombin
antibodi
prophylaxi
could
theoret
allow
decreas
convent
antimicrobi
usag
henc
recent
effort
clinic
develop
programm
intend
demonstr
mab
bacteri
pathogen
protect
risk
patient
eg
prevent
aureu
ventilatorassoci
pneumonia
colon
mechan
ventil
patient
intens
care
unit
clinicaltrialsgov
mab
may
provid
broad
neutral
potent
activ
highli
conserv
viral
epitop
altern
antibodi
target
receptor
coreceptor
locat
host
cell
research
still
infanc
mab
recogn
viral
infect
cell
induc
antibodydepend
cytotox
may
offer
addit
mechan
action
hitherto
mab
licens
hiv
rescu
therapi
adult
rsv
infect
prevent
highrisk
children
whilst
ibalizumab
target
conform
epitop
tcell
receptor
block
cell
entri
candid
develop
either
also
target
host
antigen
altern
directli
bind
antigen
research
includ
promis
bispecif
trispecif
broadli
neutral
antibodi
regard
rsv
palivizumab
interfer
viru
attach
fusion
bind
rsv
f
protein
present
rsv
research
focus
extend
halflif
rsv
mab
aim
protect
infant
throughout
first
rsv
season
singl
dose
administr
current
studi
viral
target
includ
influenza
ebola
zika
recent
viral
outbreak
brought
heighten
awar
prepar
emerg
infect
threat
mab
could
potenti
indic
treatment
infect
individu
could
well
provid
target
prophylaxi
individu
protect
transmiss
interrupt
possibl
chang
dynam
nascent
epidem
exampl
within
context
ongo
product
develop
target
influenza
promis
result
obtain
ferret
model
earli
clinic
develop
broadli
neutral
mab
might
suitabl
emerg
pandem
outbreak
least
specif
atrisk
group
expos
contact
healthcar
profession
scenario
could
use
bridg
time
gap
avail
strainspecif
vaccin
potenti
provid
compar
efficaci
product
replac
current
indic
hyperimmun
sera
mab
deserv
explor
take
account
feasibl
issu
relat
clinic
develop
exampl
face
period
outbreak
diphtheria
variou
world
region
global
short
suppli
equin
diphtheria
antitoxin
provid
new
impetu
develop
suitabl
monoclon
antibodi
altern
far
though
activ
advanc
respect
rabi
least
two
differ
product
consid
one
singl
human
monoclon
antibodi
siirmab
recent
complet
noninferior
control
trial
conclud
potenti
safe
potent
altern
human
rabi
immunoglobulincontain
postexposur
prophylaxi
regimen
illustr
ongo
effort
antiinfect
mab
constitut
thrive
focu
research
order
becom
success
multipl
challeng
need
overcom
first
technic
barrier
remain
instanc
proper
select
bacteri
target
remain
fraught
uncertainti
highli
conserv
outer
membran
protein
may
mask
henc
unavail
bind
antibodi
convers
epitop
locat
exopolysaccharid
typic
conserv
ie
differ
serotyp
exist
pose
limit
effect
target
singl
monoclon
antibodi
moreov
bacteri
defenc
mechan
develop
respons
host
immunoglobulin
eg
product
antibodi
degrad
proteinas
imped
success
antibodybas
therapi
viral
infect
singl
last
treatment
hamper
face
multipl
strain
rapid
evolut
select
escap
mutant
addit
pathogen
viraemia
often
peak
appear
symptom
circumst
rapid
pointofcar
diagnost
may
fundament
success
intervent
allow
prompt
therapi
initi
risk
develop
seriou
ill
second
regulatori
product
approv
pathway
well
optim
emerg
threat
inde
small
number
patient
unpredict
outbreak
dynam
may
imped
conduct
confirmatori
control
clinic
trial
also
human
challeng
studi
provid
support
evid
protect
limit
number
condit
absenc
adequ
risk
mitig
approach
expect
feasibl
emerg
infect
altern
howev
threat
lack
sustain
humantohuman
transmiss
assess
could
base
mainli
data
obtain
anim
challeng
studi
pharmacokinet
safeti
evalu
product
healthi
volunt
condit
anim
model
establish
suffici
repres
human
diseas
avail
protocol
test
effect
safeti
therapeut
field
time
outbreak
would
probabl
constitut
condit
licens
third
busi
model
potenti
market
vari
depend
diseas
target
whole
invest
product
develop
hinder
lack
clariti
posit
use
mab
amongst
prevent
therapeut
option
uncertainti
remaindfor
instanc
select
appropri
trial
endpoint
delin
popul
best
suit
intervent
addit
develop
constrain
high
invest
expens
amidst
unsur
futur
return
appropri
price
consid
prerequisit
market
success
henc
increas
streamlin
optim
innov
process
eg
qualitybydesign
may
exert
downward
pressur
cost
moreov
research
new
deliveri
method
expand
intensifi
ensur
conveni
administr
larg
number
peopl
may
entail
develop
novel
intramuscular
inhal
formul
respect
dna
plasmiddeliv
mab
produc
muscl
cell
vivo
singl
potenti
way
circumv
limit
immunoglobulin
g
administr
nextgener
mab
might
offer
opportun
even
allow
singl
product
target
multipl
pathogen
regulatori
viewpoint
tool
avail
european
union
ensur
swift
evalu
process
earli
access
market
includ
specif
scientif
guidanc
dedic
advic
compani
tabl
regard
obtain
compli
european
medicin
agenc
scientif
advic
shown
predict
regulatori
success
concern
emerg
infect
broad
stakehold
engag
nation
intern
public
health
agenc
privat
sector
fund
organ
regulatori
author
advoc
argu
may
entail
creation
independ
global
agenc
develop
implement
coher
strategi
global
bioprepared
although
research
clinic
develop
mab
intensifi
remain
proven
new
dawn
horizon
product
class
becom
commonplac
fight
array
infect
inroad
made
far
illustr
licens
mab
infecti
agent
associ
toxin
howev
broader
antiinfect
potenti
fulli
exploit
scientif
regulatori
commerci
barrier
develop
need
address
amongst
initi
earli
dialogu
regulatori
author
encourag
ensur
streamlin
develop
enabl
earli
access
patient
orphan
drug
medicin
diagnosi
prevent
treatment
lifethreaten
chronic
debilit
condit
rare
medicin
unlik
gener
suffici
profit
justifi
research
develop
cost
incent
appli
eg
fee
reduct
prime
prioriti
scheme
support
develop
medicin
major
interest
target
unmet
medic
need
continu
support
earli
interact
review
sa
key
develop
mileston
involv
addit
stakehold
hta
potenti
combin
one
sever
earli
access
tool
time
maa
earli
access
acceler
review
reduc
evalu
time
frame
rapid
assess
medicin
major
interest
public
health
especi
one
therapeut
innov
unmet
medic
need
condit
maa
earlier
author
medicin
patient
unmet
medic
need
basi
less
complet
clinic
data
elig
includ
medicin
serious
debilit
lifethreaten
diseas
emerg
situat
orphan
drug
comprehens
data
expect
gener
author
within
agre
time
frame
riskbenefit
ratio
clearli
posit
time
approv
compassion
use
benefit
serious
ill
patient
treat
satisfactorili
enrol
ongo
clinic
trial
pertain
unauthor
medicin
product
chronic
serious
debilit
lifethreaten
diseas
satisfactori
treatment
author
eu
target
group
patient
rather
individu
undergo
central
maa
clinic
trial
ema
european
medicin
agenc
fda
us
food
drug
administr
hta
health
technolog
assess
bodi
maa
market
author
applic
sa
scientif
advic
